2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T63c,Non-scarring alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium, is highly prevalent and often associated with significant psychosocial burden. Although treatments such as minoxidil and finasteride are available, variability in response and tolerability concerns have increased interest in alternative therapeutic approaches. Polyphenolic compounds have attracted attention due to their antioxidant, anti-inflammatory, and immunomodulatory properties. This systematic review and meta-analysis evaluated the efficacy of oral and topical polyphenolic interventions for hair regeneration in adults with non-scarring alopecia. A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL was conducted according to PRISMA 2020 guidelines (PROSPERO: CRD420251230149). Randomized, blinded controlled trials were included. Primary outcomes were objective trichoscopic measures, including hair density and total area hair count. Thirty-two randomized controlled trials involving 2,183 participants were analyzed. Compared with controls, polyphenolic interventions significantly improved hair density (SMD 0.90; 95% CI 0.51-1.30) and total area hair count (SMD 1.03; 95% CI 0.42-1.63), although substantial heterogeneity was observed. Direct comparisons with minoxidil did not show significant differences in overall hair count outcomes. Current evidence suggests that selected polyphenolic formulations may represent a potential adjunctive therapeutic approach in non-scarring alopecia, though further standardized and long-term trials are warranted.31:T8a8,The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking. To create an expert consensus statement for LDOM prescribing for patients with hair loss. The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale. Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus. This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.32:Ta86,ImportanceThe results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking.ObjectiveTo create an expert consensus statement for LDOM prescribing for patients with hair loss.Evidence ReviewThe current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale.FindingsOver 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus.Conclusions and RelevanceThis international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Telogen Effluvium: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Telogen Effluvium (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Telogen%20Effluvium\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Telogen Effluvium\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Telogen%20Effluvium\"}]}}"}}]],["$","$L2f",null,{"title":"Telogen Effluvium: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Telogen Effluvium with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1007/s13555-026-01866-z","pmid":"42449043","title":"A 6-Month Prospective, Open-Label, Randomized Study Showing Increased Hair Growth Rate in Women Using Multi-Targeting Hair Growth Nutraceuticals","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-07-14T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01866-z","source_score":30,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-19T13:39:54.130Z","updated_at":"2026-07-19T13:39:54.130Z","tags":[{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"brand","value":"Nutrafol","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"condition","value":"Hair Thinning","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"generic","value":"ashwagandha","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"generic","value":"saw palmetto","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"generic","value":"tocotrienols","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"modality","value":"Nutraceutical Supplement","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"sample_size","value":"n=180","value_numeric":180},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"study_design","value":"Prospective Open-Label Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"No placebo control group was included; all comparisons are within-subject vs. baseline, limiting causal conclusions.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"Seven participants were concurrently using incretin-based therapies (e.g., GLP-1 agonists); post hoc subgroup results are pending a separate publication.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"The postpartum formula arm enrolled non-postpartum women as surrogates; results may not directly apply to postpartum patients.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"The study is described as 'randomized' in the title, but randomization appears to be by supplement group assignment based on life stage/diet, not blinded allocation — the study is effectively open-label observational within pre-assigned cohorts.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"The study was fully funded by Nutraceutical Wellness, Inc. (Nutrafol manufacturer), and two authors are company employees — high conflict-of-interest risk.","value_numeric":null}],"summaries":{"what_studied":"Four oral botanical-based hair growth nutraceuticals (HGNs; Nutrafol Women Original, Advanced/vegan, Women's Balance for menopause, and Postpartum formulas) were evaluated over 6 months in 180 women aged 18–70 with self-reported and dermatologist-confirmed hair thinning, with assessments at days 0, 90, and 180 using Canfield HairMetrix® phototrichogram for linear hair growth rate (LHGR), hair counts, and anagen/telogen phases.","key_result":"All four HGN groups achieved statistically significant increases in LHGR by day 90, sustained through day 180 (p < 0.0001 for all groups), with relative gains of 18.6–36.7% above baseline (absolute gains ~0.04–0.06 mm/24 h). Terminal hair counts rose 6.0–7.9% and anagen hair counts rose 9.7–19.8% across groups at day 180; total scalp coverage increased 5.3–8.5%. 89–98% of participants subjectively agreed their hair was growing faster or longer.","limitations":"- Open-label, no placebo arm; placebo effect and natural temporal fluctuations in hair growth cannot be excluded.\n- The postpartum formula was tested in non-postpartum women to allow stable baseline measurement, limiting direct generalizability to the intended population.\n- Two of four authors are employees of the sponsor (Nutraceutical Wellness, Inc.), and the study was fully industry-funded, raising conflict-of-interest concern.","practice_takeaway":"These botanical-based oral supplements showed measurable increases in LHGR and hair counts in women with thinning hair, but the lack of a placebo control limits causal inference. Clinicians can consider them as adjuncts to established therapies, while awaiting placebo-controlled replication."}},{"doi":"10.1097/dss.0000000000005176","pmid":"42210891","title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms","journal_title":"Dermatologic Surgery","journal_issn":"1076-0512","published_at":"2026-05-18T00:00:00.000Z","url":"https://doi.org/10.1097/dss.0000000000005176","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-04T13:23:42.968Z","updated_at":"2026-06-04T13:23:42.968Z","tags":[{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"brand","value":"Mounjaro","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"brand","value":"Ozempic","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"brand","value":"Wegovy","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"brand","value":"Zepbound","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"condition","value":"Alopecia","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"condition","value":"Androgenic Alopecia","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"condition","value":"Inflammatory Alopecia","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"generic","value":"semaglutide","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"generic","value":"tirzepatide","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"study_design","value":"Scoping Review","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"warning","value":"Brand name tags for semaglutide and tirzepatide are inferred from common clinical knowledge; the abstract does not explicitly list brand names.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"warning","value":"Study design classification as 'Scoping Review' is based on the abstract's explicit description; no further methodological details were available to confirm rigor.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005176","tag_type":"warning","value":"The full article text was not accessible — only the abstract and a publisher permissions page were provided. Specific study counts, patient numbers, effect sizes, and cited references could not be verified from the source.","value_numeric":null}],"summaries":{"what_studied":"This scoping review evaluated the prevalence and mechanisms of alopecia associated with GLP-1 receptor agonists (GLP-1RAs), comparing effects across agents and hair loss types, using PubMed literature published up to April 2026.","key_result":"Evidence links GLP-1RAs — especially tirzepatide and semaglutide — to telogen effluvium and androgenic alopecia, with risk potentially higher at longer durations, greater weight loss, and higher doses. A smaller body of evidence suggests GLP-1RAs may *improve* inflammatory alopecia in patients with metabolic dysfunction.","limitations":"- Scoping review design limits causal inference; no pooled quantitative data or meta-analysis.\n- Full text of the article was not available for extraction — only the abstract was substantive; specific study counts, patient numbers, and effect sizes could not be verified.\n- Conflicting evidence across included studies makes definitive conclusions difficult.","practice_takeaway":"Counsel patients starting GLP-1RAs — particularly tirzepatide or semaglutide — about the risk of telogen effluvium and androgenic alopecia, especially with rapid or significant weight loss. Proactive monitoring and early treatment referral are reasonable in at-risk patients."}},{"doi":"10.1080/09546634.2026.2654112","pmid":"42057730","title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials","journal_title":"Journal of Dermatological Treatment","journal_issn":"0954-6634","published_at":"2026-04-30T00:00:00.000Z","url":"https://doi.org/10.1080/09546634.2026.2654112","source_score":6,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-08","doi":"10.1080/09546634.2026.2654112","days":"7","issn":"0954-6634","rank":"6","field":"Clinical Medicine","score":"6","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1080/09546634.2026.2654112","title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials.","journal":"The Journal of dermatological treatment","methods":"","results":"Thirty-two randomized controlled trials involving 2,183 participants were analyzed. Compared with controls, polyphenolic interventions significantly improved hair density (SMD 0.90; 95% CI 0.51-1.30) and total area hair count (SMD 1.03; 95% CI 0.42-1.63), although substantial heterogeneity was observed. Direct comparisons with minoxidil did not show significant differences in overall hair count outcomes.","abstract":"$30","keywords":["Polyphenols","androgenetic alopecia","botanical extracts","hair density","meta-analysis","randomized controlled trials"],"pubmed_id":"42057730","conclusions":"","publication_date":"2026-04-30T00:00:00"},"crossref":{"DOI":"10.1080/09546634.2026.2654112","URL":"https://doi.org/10.1080/09546634.2026.2654112","ISSN":["0954-6634","1471-1753"],"link":[{"URL":"https://www.tandfonline.com/doi/pdf/10.1080/09546634.2026.2654112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials"],"author":[{"given":"Chaimae","family":"El Ammari","sequence":"first","affiliation":[{"name":"UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"},{"name":"Group of Metabolism and Gene Regulation, UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"}]},{"given":"Ana María","family":"García-Muñoz","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]},{"given":"Rubén","family":"Zapata-Pérez","sequence":"additional","affiliation":[{"name":"UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"},{"name":"Group of Metabolism and Gene Regulation, UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"}]},{"given":"Rubén","family":"Rabadán-Ros","sequence":"additional","affiliation":[{"name":"UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"},{"name":"Group of Metabolism and Gene Regulation, UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"}]},{"given":"Carmen","family":"Lucas-Abellán","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]},{"given":"Rebeca","family":"González-Louzao","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]},{"given":"Desirée","family":"Victoria-Montesinos","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]}],"issued":{"date-parts":[[2026,4,30]]},"member":"301","prefix":"10.1080","source":"Crossref","volume":"37","created":{"date-time":"2026-04-30T08:17:27Z","timestamp":1777537047000,"date-parts":[[2026,4,30]]},"indexed":{"date-time":"2026-05-04T03:44:07Z","timestamp":1777866247049,"date-parts":[[2026,5,4]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000,"date-parts":[[2026,4,30]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.tandfonline.com/doi/full/10.1080/09546634.2026.2654112"}},"subtitle":[],"assertion":[{"name":"peerreview_statement","label":"Peer Review Statement","order":1,"value":"The publishing and review policy for this title is described in its Aims & Scope."},{"URL":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijdt20","name":"aims_and_scope_url","label":"Aim & Scope","order":2,"value":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijdt20"},{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2026-02-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-03-28"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-04-30"}],"deposited":{"date-time":"2026-04-30T08:17:33Z","timestamp":1777537053000,"date-parts":[[2026,4,30]]},"issn-type":[{"type":"print","value":"0954-6634"},{"type":"electronic","value":"1471-1753"}],"published":{"date-parts":[[2026,4,30]]},"publisher":"Informa UK Limited","reference":[{"DOI":"10.1016/j.reth.2022.10.005","key":"e_1_3_3_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/lsm.23017","key":"e_1_3_3_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S284435","key":"e_1_3_3_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_5_1","year":"2017","issue":"6","author":"Juárez-Rendón KJ","volume":"115","first-page":"e404","unstructured":"Juárez-Rendón KJ, Rivera Sánchez G, Reyes-López MÁ, et al. Alopecia Areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404–e411. 11.","article-title":"Alopecia Areata. Current situation and perspectives","journal-title":"Arch Argent Pediatr","doi-asserted-by":null},{"DOI":"10.3390/ph18020138","key":"e_1_3_3_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/molecules27227832","key":"e_1_3_3_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.n71","key":"e_1_3_3_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/9781119536604","key":"e_1_3_3_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/9781119536604.ch8","key":"e_1_3_3_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_11_1","year":"2018","issue":"5","author":"Ablon G","volume":"17","first-page":"558","unstructured":"Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558–565.","article-title":"A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.3390/life15030500","key":"e_1_3_3_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.16778","key":"e_1_3_3_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.56609/jac.v41i2.276","key":"e_1_3_3_14_1","year":"2023","issue":"2","author":"Biasio FD","volume":"41","first-page":"28","unstructured":"Biasio FD, Ielpo A, Santarsiere L, et al. A randomized double-blind placebo-controlled clinical trial to evaluate the effect of an Annurca apple supplement formula in androgenic alopecia. J Appl Cosmetol. 2023;41(2):28–46.","article-title":"A randomized double-blind placebo-controlled clinical trial to evaluate the effect of an Annurca apple supplement formula in androgenic alopecia","journal-title":"J Appl Cosmetol","doi-asserted-by":"crossref"},{"DOI":"10.1002/hsr2.1045","key":"e_1_3_3_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ics.12783","key":"e_1_3_3_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2174/0118743722294678240502110214","key":"e_1_3_3_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1155/2014/549721","key":"e_1_3_3_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1248/bpb.b15-00387","key":"e_1_3_3_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.22159/ajpcr.2021.v14i8.41859","key":"e_1_3_3_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/09546639609086878","key":"e_1_3_3_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/srt.13448","key":"e_1_3_3_22_1","year":"2023","issue":"9","author":"Ham S","volume":"29","first-page":"e13448","unstructured":"Ham S, Lee YI, Kim IA, et al. Efficacy and safety of persimmon leaf formulated with green tea and sophora fruit extracts (BLH308) on hair growth: a randomized, double-blind, placebo-controlled clinical trial. Skin Res Technol. 2023;29(9):e13448.","article-title":"Efficacy and safety of persimmon leaf formulated with green tea and sophora fruit extracts (BLH308) on hair growth: a randomized, double-blind, placebo-controlled clinical trial","journal-title":"Skin Res Technol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.13734","key":"e_1_3_3_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/antiox14040477","key":"e_1_3_3_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu17050767","key":"e_1_3_3_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.fshw.2023.02.043","key":"e_1_3_3_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_27_1","year":"2013","issue":"1","author":"Loing E","volume":"64","first-page":"45","unstructured":"Loing E, Lachance R, Ollier V, et al. A new strategy to modulate alopecia using a combination of two specific and unique ingredients. J Cosmet Sci. 2013;64(1):45–58.","article-title":"A new strategy to modulate alopecia using a combination of two specific and unique ingredients","journal-title":"J Cosmet Sci","doi-asserted-by":null},{"DOI":null,"key":"e_1_3_3_28_1","year":"2020","issue":"10","author":"Lueangarun S","volume":"13","first-page":"32","unstructured":"Lueangarun S, Panchaprateep R. An herbal extract combination (Biochanin A, Acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial. J Clin Aesthetic Dermatol. 2020;13(10):32–37.","article-title":"An herbal extract combination (Biochanin A, Acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial","journal-title":"J Clin Aesthetic Dermatol","doi-asserted-by":null},{"DOI":"10.1111/jocd.14931","key":"e_1_3_3_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/biom13040699","key":"e_1_3_3_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_31_1","year":"2015","issue":"1","author":"Panahi Y","volume":"13","first-page":"15","unstructured":"Panahi Y, Taghizadeh M, Marzony ET, et al. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15–21.","article-title":"Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.15570/actaapa.2018.13","key":"e_1_3_3_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000540081","key":"e_1_3_3_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2011.568470","key":"e_1_3_3_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/27683605251363174","key":"e_1_3_3_35_1","year":"2025","issue":"10","author":"Revathi R","volume":"31","first-page":"921","unstructured":"Revathi R, Suhag D. Amaranthus extract promotes healthy follicles and anagen hair density-A randomized placebo-controlled, double-blinded study. J Integr Complement Med. 2025;31(10):921–931.","article-title":"Amaranthus extract promotes healthy follicles and anagen hair density-A randomized placebo-controlled, double-blinded study","journal-title":"J Integr Complement Med","doi-asserted-by":"crossref"},{"DOI":"10.1002/ptr.800","key":"e_1_3_3_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.12753","key":"e_1_3_3_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/2515690X241291141","key":"e_1_3_3_38_1","year":"2024","issue":null,"author":"Tanuphol N","volume":"29","first-page":null,"unstructured":"Tanuphol N, Waranuch N, Wisuitiprot V, et al. Effectiveness and safety of hair growth formulation containing Tectona grandis L.f (teak) leaf extract: a randomized, double-blind, placebo-controlled study on males with androgenic alopecia. J Evid-Based Integr Med. 2024;29:2515690X241291141.","article-title":"Effectiveness and safety of hair growth formulation containing Tectona grandis L.f (teak) leaf extract: a randomized, double-blind, placebo-controlled study on males with androgenic alopecia","journal-title":"J Evid-Based Integr Med","doi-asserted-by":"crossref"},{"DOI":"10.1089/jmf.2017.0016","key":"e_1_3_3_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/cosmetics11050146","key":"e_1_3_3_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.14158","key":"e_1_3_3_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/tjd.tjd_41_22","key":"e_1_3_3_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2021.1945527","key":"e_1_3_3_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2004.05785.x","key":"e_1_3_3_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1017/jns.2016.41","key":"e_1_3_3_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.0007-0963.2001.04558.x","key":"e_1_3_3_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/DDDT.S327378","key":"e_1_3_3_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"update-policy":"https://doi.org/10.1080/tandf_crossmark_01","alternative-id":["10.1080/09546634.2026.2654112"],"article-number":"2654112","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2026,12,31]]},"reference-count":46,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,30]]},"references-count":46,"short-container-title":["Journal of Dermatological Treatment"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1080/09546634.2026.2654112","is_oa":true,"title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials","updated":"2026-05-06T13:23:02+00:00","published_date":"2026-04-30","best_oa_location":{"url":"https://doi.org/10.1080/09546634.2026.2654112","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1080/09546634.2026.2654112"}}},"created_at":"2026-05-14T13:22:51.771Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"generic","value":"finasteride","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"modality","value":"Polyphenolic Compound","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"sample_size","value":"n=2183","value_numeric":2183},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"Effect sizes are reported as standardized mean differences; absolute changes in hair count or density were not provided.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"No specific polyphenolic compounds or brand names are named in the abstract; the exact agents evaluated remain unclear from available text.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"Specific polyphenolic agents, dosing, and treatment durations varied and were not detailed in the summary.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"Substantial heterogeneity limits confidence in pooled effect estimates.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"The meta-analysis pools multiple distinct polyphenolic compounds (oral and topical) across different alopecia subtypes, which likely contributes to the noted substantial heterogeneity and limits interpretability of the pooled SMDs.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"The PROSPERO registration number (CRD420251230149) could not be independently verified; clinicians should confirm registration status before citing this review as pre-registered evidence.","value_numeric":null}],"summaries":{"limitations":"There was substantial heterogeneity across trials. Long-term and standardized data are lacking.","what_studied":"A systematic review and meta-analysis of randomized, blinded controlled trials tested oral and topical polyphenolic compounds versus controls in adults with non-scarring alopecia. Primary outcomes were trichoscopic hair density and total area hair count.","key_result":"Across 32 RCTs (n=2,183), polyphenolic interventions improved hair density (SMD 0.90; 95% CI 0.51–1.30) and total area hair count (SMD 1.03; 95% CI 0.42–1.63) versus controls; direct comparisons with minoxidil showed no significant difference in overall hair count.","practice_takeaway":"Selected polyphenolic formulations may raise hair density and counts in adults with non-scarring alopecia, but effects vary and they do not outperform minoxidil in head-to-head trials. Use as adjuncts should await more standardized, longer-term studies."}},{"doi":"10.1001/jamadermatol.2024.4593","pmid":"39565602","title":"Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-11-20T00:00:00.000Z","url":"https://escholarship.org/uc/item/2pp1b5gc","source_score":91,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-11-24","doi":"10.1001/jamadermatol.2024.4593","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"91","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.4593","title":"Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement.","journal":"JAMA dermatology","methods":"","results":"","abstract":"$31","keywords":[],"pubmed_id":"39565602","conclusions":"","publication_date":"2024-11-20T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.4593","URL":"https://doi.org/10.1001/jamadermatol.2024.4593","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2826573/jamadermatology_akiska_2024_cs_240009_1736781549.6292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"87","type":"journal-article","issue":"1","score":1,"title":["Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss"],"author":[{"given":"Yagiz Matthew","family":"Akiska","sequence":"first","affiliation":[{"name":"George Washington University School of Medicine & Health Sciences, Washington, DC"}]},{"given":"Paradi","family":"Mirmirani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Permanente Medical Group, Vallejo, California"}]},{"given":"Ingrid","family":"Roseborough","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Erin","family":"Mathes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Andrew","family":"Ambrosy","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, San Francisco"},{"name":"Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California"}]},{"given":"Crystal","family":"Aguh","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine, Baltimore, Maryland"}]},{"given":"Wilma","family":"Bergfeld","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Valerie D.","family":"Callender","sequence":"additional","affiliation":[{"name":"Callender Dermatology, Washington, DC"},{"name":"Howard University College of Medicine, Washington, DC"},{"name":"Callendar Cosmetic Center, Baltimore, Maryland"}]},{"given":"Leslie","family":"Castelo-Soccio","sequence":"additional","affiliation":[{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland"}]},{"given":"George","family":"Cotsarelis","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}]},{"given":"Brittany Gareth","family":"Craiglow","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}]},{"given":"Nisha S.","family":"Desai","sequence":"additional","affiliation":[{"name":"DermDX New England, Sonic Healthcare, Brighton, Massachusetts"}]},{"given":"Isabella","family":"Doche","sequence":"additional","affiliation":[{"name":"University of São Paulo Medical School, São Paulo, Brazil"}]},{"given":"Bruna","family":"Duque-Estrada","sequence":"additional","affiliation":[{"name":"Instituto de Dermatologia Prof Rubem David Azulay, Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Medical University of South Carolina, Charleston, South Carolina"}]},{"given":"Carolyn","family":"Goh","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}]},{"given":"Lynne J.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"DermDX New England, Sonic Healthcare, Brighton, Massachusetts"},{"name":"Department of Dermatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}]},{"given":"Ramon","family":"Grimalt","sequence":"additional","affiliation":[{"name":"Universitat Internacional de Catalunya, Barcelona, Spain"}]},{"given":"Ali","family":"Jabbari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Iowa, Iowa City, Iowa"},{"name":"Iowa City Veterans Affairs Medical Center, Iowa City, Iowa"}]},{"given":"Victoria","family":"Jolliffe","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, United Kingdom"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}]},{"given":"Charlotte","family":"LaSenna","sequence":"additional","affiliation":[{"name":"University of Wisconsin–Madison"}]},{"given":"Yolanda","family":"Lenzy","sequence":"additional","affiliation":[{"name":"Lenzy Dermatology & Hair Loss Center, Chicopee, Massachusetts"},{"name":"Department of Dermatology, University of Connecticut, Farmington"}]},{"given":"Jenna C.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Nino","family":"Lortkipanidze","sequence":"additional","affiliation":[{"name":"David Tvildiani Medical University, Tbilisi, Georgia"}]},{"given":"Kristen I.","family":"Lo Sicco","sequence":"additional","affiliation":[{"name":"The Ronald O Perelman Department of Dermatology, New York University Langone Health, New York"}]},{"given":"Amy","family":"McMichael","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}]},{"given":"Nekma","family":"Meah","sequence":"additional","affiliation":[{"name":"Mersey and West Lancashire NHS Trust, St Helens, United Kingdom"},{"name":"Faculty of Biology, Medicine and Health, Manchester University, Manchester, United Kingdom"}]},{"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[{"name":"University of California, Irvine"}]},{"given":"Mariya","family":"Miteva","sequence":"additional","affiliation":[{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, Florida"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School, Brigham & Women’s Hospital, Boston, Massachusetts"}]},{"given":"Yuliya","family":"Ovcharenko","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Immunology, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine"}]},{"given":"Melissa","family":"Piliang","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Department of Experimental, Diagnostic and Specialty Medicine Alma Mater Studiorum, University of Bologna, Bologna, Italy"}]},{"given":"Adriana","family":"Rakowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Warsaw, Warsaw, Poland"}]},{"given":"Kimberly S.","family":"Salkey","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University, Richmond, Virginia"}]},{"given":"Adriana","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Santa Monica Dermatology Group, Santa Monica, California"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine, New York"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology, Victoria, Australia"},{"name":"University of Melbourne, Melbourne, Victoria, Australia"}]},{"given":"Poonkiat","family":"Suchonwanit","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand"}]},{"given":"Susan","family":"Taylor","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"University of Miami, Miami, Florida"}]},{"given":"Sergio","family":"Vañó-Galván","sequence":"additional","affiliation":[{"name":"Dermatology Service, Ramon y Cajal Hospital and Grupo Pedro Jaen Clinic, IRYCIS, University of Alcala, Madrid, Spain"}]},{"given":"Dmitri Robert","family":"Wall","sequence":"additional","affiliation":[{"name":"Hair Restoration Blackrock, Dublin, Ireland"},{"name":"National and International Skin Registry Solutions (NISR), Belfield, Ireland"},{"name":"Charles Institute of Dermatology, University College Dublin, Dublin, Ireland"},{"name":"The Mater Misericordiae University Hospital, Dublin, Ireland"}]},{"given":"Jennifer M.","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Solano Dermatology Associates, Fairfield, California"}]}],"issued":{"date-parts":[[2025,1,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2024-11-20T16:00:33Z","timestamp":1732118433000,"date-parts":[[2024,11,20]]},"indexed":{"date-time":"2025-09-12T19:31:20Z","timestamp":1757705480748,"date-parts":[[2025,9,12]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2826573"}},"subtitle":["An International Modified Delphi Consensus Statement"],"deposited":{"date-time":"2025-01-15T16:01:09Z","timestamp":1736956869000,"date-parts":[[2025,1,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,1,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":null,"key":"dcs240009r1","year":"2017","issue":"6","author":"Phillips","volume":"96","first-page":"371","unstructured":null,"article-title":"Hair loss: common causes and treatment.","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1056/NEJM199909233411307","key":"dcs240009r2","year":"1999","issue":"13","author":"Price","volume":"341","first-page":"964","unstructured":null,"article-title":"Treatment of hair loss.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2020.19313","key":"dcs240009r3","year":"2021","issue":"9","author":"Mirmirani","volume":"325","first-page":"878","unstructured":null,"article-title":"Diagnosis and treatment of nonscarring hair loss in primary care in 2021.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.13950","key":"dcs240009r4","year":"2020","issue":"6","author":"Lemes","volume":"33","first-page":null,"unstructured":null,"article-title":"Topical and oral minoxidil for hair disorders in pediatric patients: what do we know so far?","journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.03.056","key":"dcs240009r5","year":"2019","issue":"5","author":"Freites-Martinez","volume":"80","first-page":"1199","unstructured":null,"article-title":"Hair disorders in cancer survivors.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2021.1945527","key":"dcs240009r6","year":"2022","issue":"4","author":"Gupta","volume":"33","first-page":"1896","unstructured":null,"article-title":"Minoxidil: a comprehensive review.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.06.1009","key":"dcs240009r8","year":"2021","issue":"3","author":"Randolph","volume":"84","first-page":"737","unstructured":null,"article-title":"Oral minoxidil treatment for hair loss: a review of efficacy and safety.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.02.054","key":"dcs240009r9","year":"2021","issue":"6","author":"Vañó-Galván","volume":"84","first-page":"1644","unstructured":null,"article-title":"Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.14106","key":"dcs240009r10","year":"2020","issue":"6","author":"Jimenez-Cauhe","volume":"33","first-page":null,"unstructured":null,"article-title":"Safety of low-dose oral minoxidil treatment for hair loss: a systematic review and pooled-analysis of individual patient data.","journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.05.026","key":"dcs240009r11","year":"2023","issue":"2","author":"Sanabria","volume":"88","first-page":"436","unstructured":null,"article-title":"Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.08.080","key":"dcs240009r12","year":"2021","issue":"3","author":"Wambier","volume":"85","first-page":"743","unstructured":null,"article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.16373","key":"dcs240009r13","year":"2023","issue":"2","author":"John","volume":"62","first-page":"257","unstructured":null,"article-title":"Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.04.030","key":"dcs240009r14","year":"2022","issue":"3","author":"de Nicolas-Ruanes","volume":"87","first-page":"700","unstructured":null,"article-title":"Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: a descriptive study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.12.073","key":"dcs240009r15","year":"2024","issue":"6","author":"Jackson","volume":"90","first-page":"1182","unstructured":null,"article-title":"Treatment for central centrifugal cicatricial alopecia—Delphi consensus recommendations.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dcs240009r16","year":"2024","issue":"3","author":"Sanfilippo","volume":"23","first-page":"136","unstructured":null,"article-title":"Survey of dermatology practitioners’ opinions and prescribing habits of oral minoxidil for the treatment of androgenetic alopecia.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/ijd.13838","key":"dcs240009r17","year":"2018","issue":"1","author":"Sinclair","volume":"57","first-page":"104","unstructured":null,"article-title":"Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.12688/f1000research.11775.1","key":"dcs240009r18","year":"2017","issue":null,"author":"Perera","volume":"6","first-page":"1650","unstructured":null,"article-title":"Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study.","journal-title":"F1000Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.02.024","key":"dcs240009r19","year":"2023","issue":"1","author":"Awad","volume":"89","first-page":"157","unstructured":null,"article-title":"Low-dose oral minoxidil improves hair density in traction alopecia.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.10.010","key":"dcs240009r20","year":"2024","issue":"2","author":"Ong","volume":"90","first-page":"425","unstructured":null,"article-title":"Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.03.040","key":"dcs240009r21","year":"2024","issue":"2","author":"Moussa","volume":"91","first-page":"346","unstructured":null,"article-title":"Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/ced/llad019","key":"dcs240009r22","year":"2023","issue":"5","author":"McFeely","volume":"48","first-page":"554","unstructured":null,"article-title":"Trichorrhexis nodosa improving with oral minoxidil: a case report.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2022.09.035","key":"dcs240009r23","year":"2022","issue":null,"author":"Trüeb","volume":"30","first-page":"97","unstructured":null,"article-title":"Serious complication of low-dose oral minoxidil for hair loss.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2022.07.044","key":"dcs240009r24","year":"2022","issue":null,"author":"Dlova","volume":"28","first-page":"94","unstructured":null,"article-title":"Pericardial, pleural effusion and anasarca: a rare complication of low-dose oral minoxidil for hair loss.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2648.2003.02537.x","key":"dcs240009r25","year":"2003","issue":"4","author":"Powell","volume":"41","first-page":"376","unstructured":null,"article-title":"The Delphi technique: myths and realities.","journal-title":"J Adv Nurs","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjqs-2015-004411","key":"dcs240009r26","year":"2016","issue":"12","author":"Ogrinc","volume":"25","first-page":"986","unstructured":null,"article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.","journal-title":"BMJ Qual Saf","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jbi.2019.103208","key":"dcs240009r27","year":"2019","issue":null,"author":"Harris","volume":"95","first-page":null,"unstructured":null,"article-title":"The REDCap consortium: building an international community of software platform partners.","journal-title":"J Biomed Inform","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.03.004","key":"dcs240009r28","year":"2020","issue":"1","author":"Meah","volume":"83","first-page":"123","unstructured":null,"article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.09.028","key":"dcs240009r29","year":"2021","issue":"6","author":"Meah","volume":"84","first-page":"1594","unstructured":null,"article-title":"The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.5839","key":"dcs240009r30","year":"2021","issue":"4","author":"Wall","volume":"157","first-page":"1","unstructured":null,"article-title":"A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.5869","key":"dcs240009r31","year":"2024","issue":"3","author":"Moussa","volume":"160","first-page":"341","unstructured":null,"article-title":"The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2017.05.014","key":"dcs240009r32","year":"2017","issue":"9","author":"Spuls","volume":"137","first-page":"2014","unstructured":null,"article-title":"The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13063-016-1765-7","key":"dcs240009r33","year":"2017","issue":"1","author":"Gerbens","volume":"18","first-page":"87","unstructured":null,"article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.","journal-title":"Trials","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16714","key":"dcs240009r34","year":"2019","issue":"4","author":"Gerbens","volume":"180","first-page":"790","unstructured":null,"article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.04.027","key":"dcs240009r35","year":"2022","issue":"2","author":"Therianou","volume":"86","first-page":"429","unstructured":null,"article-title":"How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dcs240009r7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Food and Drug Administration. Loniten (minoxidil). Pfizer Inc. January 2015. Accessed October 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018154s026lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,1,1]]},"reference-count":35,"published-online":null,"references-count":35,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":5},"unpaywall":{"doi":"10.1001/jamadermatol.2024.4593","is_oa":true,"title":"Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss","updated":"2025-09-06T02:51:56+00:00","published_date":"2024-11-20","best_oa_location":{"url":"https://escholarship.org/uc/item/2pp1b5gc","pmh_id":"oai:escholarship.org:ark:/13030/qt2pp1b5gc","url_for_pdf":null,"url_for_landing_page":"https://escholarship.org/uc/item/2pp1b5gc"}}},"created_at":"2025-09-20T03:51:21.142Z","updated_at":"2025-09-20T06:15:05.187Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"brand","value":"Loniten","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Central Centrifugal Cicatricial Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Chemotherapy-Induced Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Endocrine Therapy-Induced Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Frontal Fibrosing Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Lichen Planopilaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"modality","value":"Vasodilator","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"sample_size","value":"n=43","value_numeric":43},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"study_design","value":"Delphi Consensus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"warning","value":"Design classification reflects an expert Delphi consensus, not patient-level comparative evidence.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"warning","value":"Pediatric dosing (<12 years) and titration protocols did not reach consensus.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"warning","value":"Percentages denote panel agreement, not treatment effect sizes or event rates.","value_numeric":null}],"summaries":{"what_studied":"An international modified Delphi process among 43 hair-loss dermatologists from 12 countries (March 21, 2023–January 22, 2024) to generate consensus recommendations for initiating low-dose oral minoxidil for hair loss, with consensus defined as ≥70% agreement.","key_result":"Across 4 rounds, 76 items reached consensus, including: consider LDOM for adults and adolescents (93.0% and 86.0%); direct benefit in AGA and age‑related thinning (97.7% each); typical starting doses—female adults 1.25 mg/day (74.4%), male adults 2.5 mg/day (74.4%)—with ranges up to 5 mg/day; avoid in pregnancy/breastfeeding (95.5%); baseline labs and ECG not routine absent precautions (90.7% and 93.0%); counsel that vasodilation effects may appear in 3–7 days, fluid retention in 4–6 weeks, and earliest efficacy at 3 months.","limitations":"Findings reflect expert opinion rather than patient outcomes; pediatric experts were underrepresented and no consensus was reached for children <12 years or for titration protocols. Guidance for patients with true minoxidil allergy remains unresolved.","practice_takeaway":"When topical minoxidil is ineffective, impractical, or irritant, experts support considering LDOM in adults and adolescents, typically starting at 1.25 mg/day (female) or 2.5 mg/day (male), individualized by risk and goals, and avoiding use in pregnancy or breastfeeding. Skip routine baseline labs/ECG unless precautions exist; monitor blood pressure and counsel patients to watch for tachycardia/dizziness within 3–7 days, edema/weight gain by 4–6 weeks, and expect earliest hair response by 3 months."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Telogen Effluvium"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Telogen Effluvium"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Telogen Effluvium"}}}]]

Papers